

# Marina Baretta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7240763/publications.pdf>

Version: 2024-02-01

25  
papers

878  
citations

933264

10  
h-index

713332

21  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1838  
citing authors

#	ARTICLE	IF	CITATIONS
1	Expanding the immunotherapy roadmap for hepatocellular carcinoma. <i>Cancer Cell</i> , 2022, 40, 252-254.	7.7	9
2	Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. <i>JCO Precision Oncology</i> , 2022, , .	1.5	19
3	Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. <i>Cancer Control</i> , 2021, 28, 107327482110099.	0.7	4
4	A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. <i>Clinical Epigenetics</i> , 2021, 13, 25.	1.8	11
5	A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. <i>Clinical and Translational Science</i> , 2021, 14, 954-963.	1.5	5
6	Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	11
7	Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. <i>Oncolimmunology</i> , 2021, 10, 2001159.	2.1	10
8	An analysis of genetic heterogeneity in untreated cancers. <i>Nature Reviews Cancer</i> , 2019, 19, 639-650.	12.8	139
9	Precision Cancer Trials With Immunomodulatory Agents. <i>Cancer Journal (Sudbury, Mass )</i> , 2019, 25, 287-295.	1.0	3
10	The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2019, 48, 585-589.	0.5	10
11	Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 570-570.	0.8	0
12	The impact of the immune microenvironment in patients with GEP-NETs.. <i>Journal of Clinical Oncology</i> , 2019, 37, 267-267.	0.8	0
13	DNA mismatch repair in cancer. , 2018, 189, 45-62.		356
14	Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?. <i>Cancer Biology and Therapy</i> , 2018, 19, 659-663.	1.5	9
15	Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e489-e498.	1.0	16
16	The role of epigenetic therapies in colorectal cancer. <i>Current Problems in Cancer</i> , 2018, 42, 530-547.	1.0	53
17	Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4151-TPS4151.	0.8	4
18	Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. <i>Gastric Cancer</i> , 2017, 20, 428-437.	2.7	5

#	ARTICLE	IF	CITATIONS
19	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017, 28, 555-561.	0.6	43
20	Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. <i>Immunotherapy</i> , 2016, 8, 1363-1369.	1.0	34
21	Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. <i>Lung Cancer</i> , 2016, 95, 82-87.	0.9	19
22	KRAS mutation in lung metastases from colorectal cancer: prognostic implications. <i>Cancer Medicine</i> , 2016, 5, 256-264.	1.3	29
23	Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. <i>Digestive and Liver Disease</i> , 2015, 47, 884-890.	0.4	59
24	Prognostic and predictive value of MET deregulation in non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2015, 3, 83.	0.7	25
25	Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities. <i>Annals of Pancreatic Cancer</i> , 0, 2, 18-18.	1.2	5